Caspofungin is a cyclic lipopeptide echinocandin antifungal (Cancidas).
5 listed companies hold an active US Type II Drug Master File for Caspofungin API, based in India (3), Taiwan (1), Netherlands (1). 4 have a regulator record of GMP manufacturing.
Ordered by score. Scores follow the published rules and are not affected by paid placement. Updated 2026-11-13.
Source: FDA Drug Master File list. Holding a DMF is a regulatory filing, not an FDA approval.
Taiwanese API maker founded in 1964, trading as Cenra API Solutions, offering CMO/CDMO services. Holds US DMFs for difelikefalin, plecanatide and setmelanotide.
Hyderabad injectables CDMO founded 1978, promoted by Fosun Pharma; FDA-inspected sites; US DMF for glatiramer acetate.
Hyderabad-based MSN Group entity holding US DMFs for 11 peptide APIs, including semaglutide and tirzepatide. MSN runs 27 plants in India, the USA and Indonesia.
Dutch holding entity of TAPI, Teva's API and CDMO business, with peptide development and GMP production across a global plant network. Holds US DMFs for 9 peptide APIs.
Privately held Hyderabad generics and API group with 36+ plants; US DMFs for semaglutide and vasopressin.
Companies holding active US DMFs for Caspofungin include Chunghwa Chemical Synthesis & Biotech Co., Ltd. (Cenra API Solutions), Gland Pharma Ltd, MSN Life Sciences Private Ltd (MSN Group), TAPI NL B.V. (TAPI) and Hetero Drugs Ltd. Other manufacturers may supply it without a US DMF.
Among listed DMF holders: India (3), Taiwan (1), Netherlands (1).
No. FDA reviews a DMF when a drug application references it and does not approve DMFs on their own.